IOVA · Iovance Biotherapeutics, Inc.
$5.13
-0.77% last session
End-of-day data · updated 2026-07-25
Market cap
$2B
Enterprise value
$2B
Trailing P/E
—
Forward P/E
-15.5
Dividend yield
—
Beta
0.69
Avg volume
15M
Employees
1K
2D change
-2.73%
5D change
-0.60%
10D change
5.27%
30D change
18.53%
60D change
21.71%
MTD change
25.69%
YTD change
82.78%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — IOVA
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-05-08
Latest call per bank · past 12 months
UBS
Neutral$4.00
-22.0% vs priceBarclays
Overweight$11.00
+114.4% vs priceWells Fargo
Overweight$14.00
+172.9% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-05-08 | Chardan Capital | Maintains | Buy | $16.00 → $14.00 |
| 2026-04-10 | Chardan Capital | Maintains | Buy | $16.00 |
| 2026-03-05 | UBS | Maintains | Neutral | $2.00 → $4.00 |
| 2026-03-03 | Citizens | Upgrade | Market Perform → Market Outperform | $0.00 → $5.00 |
| 2026-02-25 | Barclays | Maintains | Overweight | $10.00 → $11.00 |
| 2026-02-25 | Citizens | Upgrade | Market Perform → Market Outperform | $0.00 → $5.00 |
| 2025-12-17 | Barclays | Maintains | Overweight | $9.00 → $10.00 |
| 2025-11-24 | Barclays | Maintains | Overweight | $4.00 → $9.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-23
- RSI (14): RSI is 62 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 23.6% above the 50-day MA ($4.15).
- Price vs 200-day MA: Trading 59.3% above the 200-day MA ($3.22).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is positive (+0.09) — short-term momentum is improving.
- 52-week range: Price sits between the 52-week low ($1.81) and high ($5.48).
IOVA Price Chart
Loading chart for IOVA…
Fundamentals
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It also develops lifileucel for the treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma (HNSCC); LN-145-S1 to treat melanoma and HNSCC; LN-145 Gen 3 and core biopsy for the treatment of NSCLC; LN-145 Gen 3 to treat melanoma and HNSCC; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001 for use in the TIL therapy treatment regimen. The company has collaborations and licensing agreements with National Institutes of Health; the National Cancer Institute; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$121B 5.3% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$69B -14.8% YTD
ARGX
argenx SE
$57B 9.2% YTD
RVMD
Revolution Medicines, Inc.
$40B 137.6% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$36B -31.7% YTD
ONC
BeOne Medicines Ltd.
$34B 7.3% YTD
RPRX
Royalty Pharma plc
$34B 53.7% YTD
ROIV
Roivant Sciences Ltd.
$25B 61.3% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.